IPF-036

Idiopathic Pulmonary Fibrosis (IPF)

Osaka 66 years old female Japan Total Cost: 215

Patient Condition

The patient was treated for shortness of breath and dry cough for 1 year after exercise, and had no history of smoking. HRCT showed grid shadows and honeycomb changes in both lungs. Lung function: FVC 60% predicted, DLCO 46% predicted. 6MWD 350m, mMRC score 2. IPF was diagnosed (GAP score of 4, stage II). Compiled with anxiety and depression.

Treatment Timeline

PhaseDetailsDate
integrated assessment
Combination therapy initiated
Combination treatment + comprehensive management (months 1-12)
Maintenance treatment (Months 13-24)

Treatment Outcome

beforeFVC accounted for 60% of predicted value, DLCO accounted for 46% of predicted value, 6MWD 350m, mMRC score 2, HADS score 12 points
afterAfter 24 months of treatment, FVC accounted for 56% of the predicted value (annual decline rate of approximately 2%), DLCO accounted for 42% of the predicted value, 6MWD was 395m (improvement of 45m), mMRC score dropped to level 1, and HADS score was 6 points
highlightCombined anti-fibrotic treatment with psychotherapy and lung rehabilitation not only delays the decline of lung function, but also significantly improves mental health and quality of life.